With 13.71 million shares changed hands, the volume of the stock remained heavier than its average volume of 45710.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $41.8 whereas the lowest price it dropped to was $11.71. The 52-week range on QNRX shows that it touched its highest point at $54.95 and its lowest point at $5.01 during that stretch. It currently has a 1-year price target of $47.50. Beta for the stock currently stands at 1.66.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of QNRX was up-trending over the past week, with a rise of 184.72%, but this was up by 171.52% over a month. Three-month performance surged to 130.60% while six-month performance rose 197.53%. The stock lost -9.99% in the past year, while it has gained 20.15% so far this year. A look at the trailing 12-month EPS for QNRX yields -479.54 with Next year EPS estimates of -15.43. For the next quarter, that number is -4.29. This implies an EPS growth rate of 71.66% for this year and 18.55% for next year. EPS is expected to grow by 47.33% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -144.01%.
Float and Shares Shorts:
On 2025-09-30, short shares totaled 5258.0, which was 89.0 higher than short shares on 1756425600. In addition to Dr. Michael Myers Ph.D. as the firm’s Co-Founder, CEO & Chairman, Ms. Denise Carter serves as its Co-Founder, COO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, QNRX reported revenue of $0.0 and operating income of -$3793179.0. The EBITDA in the recently reported quarter was -$3762175.0 and diluted EPS was -$219.8.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for QNRX since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With QNRX analysts setting a high price target of 70.0 and a low target of 25.0, the average target price over the next 12 months is 40.66667. Based on these targets, QNRX could surge 241.46% to reach the target high and rise by 21.95% to reach the target low. Reaching the average price target will result in a growth of 98.37% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$49.82694 being high and -$95.77306 being low. For QNRX, this leads to a yearly average estimate of -$72.8. The surprise factor in the prior quarter was -$4.2. Based on analyst estimates, the high estimate for the next quarter is -$1.97 and the low estimate is -$1.97. The average estimate for the next quarter is thus -$1.97.
